Competact

pioglitazone / metformin

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Competact. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Competact.

: Competact is a medicine that is available as tablets containing two active substances, pioglitazone (15 mg) and metformin hydrochloride (850 mg).

: Competact is used in adults (particularly those who are overweight) who have type 2 diabetes. Competact is used in patients who are not satisfactorily controlled on metformin (a diabetes medicine) used on its own and at the maximum possible dose.
The medicine can only be obtained with a prescription.

: The usual dose of Competact is one tablet taken twice a day. Patients changing from metformin only to Competact may need to slowly introduce pioglitazone until a dose of 30 mg per day is reached. It is possible to change to Competact directly from metformin if appropriate. Taking Competact with or just after food may reduce any stomach problems caused by metformin. Elderly patients should have their kidney function monitored regularly.
Treatment with Competact should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. At subsequent reviews, prescribers should confirm that benefits to patients are maintained.

: Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Competact contains two active substances which each have a different mode of action. Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut. As a result of the action of both active substances, the blood glucose is reduced and this helps to control type-2 diabetes.

: Pioglitazone on its own has been approved in the EU under the name Actos and can be used with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone. Three studies of Actos used with metformin as separate tablets were used to support the use of Competact in the same indication. The studies lasted from 4 months to 2 years and involved 1,305 patients who took the combination. They measured the level in the blood of a substance (HbA1c), which gives an indication of how well the blood glucose is controlled.

: In all studies, adding pioglitazone 30 mg to metformin led to an improvement in the control of blood glucose, with levels of HbA1c further decreasing by 0.64 to 0.89% compared with the levels on metformin alone.

: At the start of treatment, abdominal pain (stomach ache), diarrhoea, loss of appetite, nausea (feeling sick) and vomiting may occur. These side effects are very common but disappear on their own in most cases. Lactic acidosis (a build-up of lactic acid in the body) is a side effect which may occur in less than 1 in 10,000 patients. Other side effects such as bone fracture, increased weight and oedema (swelling) may occur in less than 1 in 10 patients. For the full list of side effects reported with Competact, see the package leaflet.
Competact must not be used in patients who have heart failure, or problems with their liver or their kidneys. Competact must not be used in patients who have a disease that causes lack of oxygen to the tissues such as a recent heart attack or shock. Competact must not be used where there is alcohol intoxication, diabetic ketoacidosis (high levels of ketones), conditions that may effects the kidneys, and during breast-feeding. It must also not be used in patients who have or have had bladder cancer or those with blood in the urine that has not yet been investigated. For the full list of restrictions, see the package leaflet.

: The CHMP concluded that the effectiveness of pioglitazone and metformin in type-2 diabetes had been shown, and that Competact simplifies treatment and improves compliance when a combination of the active substances is required. The Committee decided that Competact’s benefits are greater than its risks and recommended that it be given marketing authorisation.

: A risk management plan has been developed to ensure that Competact is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Competact, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, the company that markets Competact will produce educational materials for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.

: The European Commission granted a marketing authorisation valid throughout the European Union, for Competact on 28 July 2006.
For more information about treatment with Competact, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Competact : EPAR - Summary for the public (PDF/78.11 KB)

First published: 31/05/2007
Last updated: 02/06/2016
- Bulgarian
  (PDF/107.13 KB)
- Croatian
  (PDF/98.46 KB)
- Czech
  (PDF/104.28 KB)
- Danish
  (PDF/77.79 KB)
- Dutch
  (PDF/77.89 KB)
- Estonian
  (PDF/76.77 KB)
- Finnish
  (PDF/76.94 KB)
- French
  (PDF/79.04 KB)
- German
  (PDF/78.92 KB)
- Greek
  (PDF/109.08 KB)
- Hungarian
  (PDF/98.69 KB)
- Italian
  (PDF/77.47 KB)
- Latvian
  (PDF/101.97 KB)
- Lithuanian
  (PDF/102.21 KB)
- Maltese
  (PDF/106.1 KB)
- Polish
  (PDF/104.48 KB)
- Portuguese
  (PDF/77.97 KB)
- Romanian
  (PDF/100.55 KB)
- Slovak
  (PDF/103.4 KB)
- Slovenian
  (PDF/97.26 KB)
- Spanish
  (PDF/78.36 KB)
- Swedish
  (PDF/78.06 KB)
List item

Competact : EPAR - Risk-management-plan summary (PDF/250.61 KB)

First published: 04/03/2021

This EPAR was last updated on 16/08/2023

Authorisation details

Product details
Name	Competact
Agency product number	EMEA/H/C/000655
Active substance	pioglitazone metformin hydrochloride
International non-proprietary name (INN) or common name	pioglitazone metformin
Therapeutic area (MeSH)	Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code	A10BD05

Publication details
Marketing-authorisation holder	CHEPLAPHARM Arzneimittel GmbH
Revision	21
Date of issue of marketing authorisation valid throughout the European Union	28/07/2006
Contact address	Ziegelhof 24 17489 Greifswald Germany

Product information

11/08/2023 Competact - EMEA/H/C/000655 - IA/0081/G

List item

Competact : EPAR - Product Information (PDF/373.22 KB)

First published: 05/10/2009
Last updated: 16/08/2023
- Bulgarian
  (PDF/478.64 KB)
- Croatian
  (PDF/453.01 KB)
- Czech
  (PDF/463.55 KB)
- Danish
  (PDF/379.12 KB)
- Dutch
  (PDF/401.07 KB)
- Estonian
  (PDF/379.14 KB)
- Finnish
  (PDF/371.39 KB)
- French
  (PDF/395.38 KB)
- German
  (PDF/428.95 KB)
- Greek
  (PDF/456.12 KB)
- Hungarian
  (PDF/473.52 KB)
- Icelandic
  (PDF/376.93 KB)
- Italian
  (PDF/381.02 KB)
- Latvian
  (PDF/448.68 KB)
- Lithuanian
  (PDF/469.55 KB)
- Maltese
  (PDF/545.91 KB)
- Norwegian
  (PDF/372.08 KB)
- Polish
  (PDF/463.68 KB)
- Portuguese
  (PDF/385.71 KB)
- Romanian
  (PDF/449.54 KB)
- Slovak
  (PDF/461.48 KB)
- Slovenian
  (PDF/510.39 KB)
- Spanish
  (PDF/393.51 KB)
- Swedish
  (PDF/418.4 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Competact : EPAR - All Authorised presentations (PDF/91.12 KB)

First published: 31/05/2007
Last updated: 16/08/2023
- Bulgarian
  (PDF/110.26 KB)
- Croatian
  (PDF/90.03 KB)
- Czech
  (PDF/128.99 KB)
- Danish
  (PDF/92.01 KB)
- Dutch
  (PDF/93.11 KB)
- Estonian
  (PDF/92.17 KB)
- Finnish
  (PDF/90.73 KB)
- French
  (PDF/89.92 KB)
- German
  (PDF/94.67 KB)
- Greek
  (PDF/106.73 KB)
- Hungarian
  (PDF/112.96 KB)
- Icelandic
  (PDF/92.77 KB)
- Italian
  (PDF/89.79 KB)
- Latvian
  (PDF/132.43 KB)
- Lithuanian
  (PDF/133.19 KB)
- Maltese
  (PDF/133.21 KB)
- Norwegian
  (PDF/92.16 KB)
- Polish
  (PDF/112.85 KB)
- Portuguese
  (PDF/90.72 KB)
- Romanian
  (PDF/101.95 KB)
- Slovak
  (PDF/127.93 KB)
- Slovenian
  (PDF/111.66 KB)
- Spanish
  (PDF/89.15 KB)
- Swedish
  (PDF/90.73 KB)

List item

Competact : EPAR - Conditions imposed on member states for safe and effective use (PDF/17.07 KB)

First published: 06/07/2012
Last updated: 06/07/2012
- Bulgarian
  (PDF/69.92 KB)
- Czech
  (PDF/46 KB)
- Danish
  (PDF/16.95 KB)
- Dutch
  (PDF/21.61 KB)
- Estonian
  (PDF/19.03 KB)
- Finnish
  (PDF/16.85 KB)
- French
  (PDF/21.04 KB)
- German
  (PDF/24.01 KB)
- Greek
  (PDF/61.99 KB)
- Hungarian
  (PDF/40.78 KB)
- Icelandic
  (PDF/19.84 KB)
- Italian
  (PDF/26.74 KB)
- Latvian
  (PDF/54.33 KB)
- Lithuanian
  (PDF/48.53 KB)
- Maltese
  (PDF/45.44 KB)
- Norwegian
  (PDF/20.23 KB)
- Polish
  (PDF/49.33 KB)
- Portuguese
  (PDF/17.05 KB)
- Romanian
  (PDF/48.43 KB)
- Slovak
  (PDF/40.93 KB)
- Slovenian
  (PDF/43.28 KB)
- Spanish
  (PDF/22.21 KB)
- Swedish
  (PDF/19.19 KB)

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.

Assessment history

Changes since initial authorisation of medicine

List item

Competact : EPAR - Procedural steps taken and scientific information after authorisation (PDF/248.32 KB)

First published: 05/10/2009
Last updated: 16/08/2023
List item

Competact-H-C-PSUSA-00002417-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/69.46 KB)

First published: 18/06/2019
EMA/241763/2019
List item

Competact-H-A-31-1432-C-655-0060 : EPAR - Assessment Report - Article 31 (PDF/568.79 KB)

Adopted

First published: 18/01/2017
Last updated: 18/01/2017
EMA/867221/2016
List item

Competact : EPAR - Scientific Conclusion (PDF/32.54 KB)

First published: 18/01/2017
Last updated: 18/01/2017
- Bulgarian
  (PDF/69.5 KB)
- Croatian
  (PDF/62.6 KB)
- Czech
  (PDF/66.59 KB)
- Danish
  (PDF/29.27 KB)
- Dutch
  (PDF/30.09 KB)
- Estonian
  (PDF/28.67 KB)
- Finnish
  (PDF/29.33 KB)
- French
  (PDF/33.77 KB)
- German
  (PDF/31.79 KB)
- Greek
  (PDF/68.71 KB)
- Hungarian
  (PDF/48.06 KB)
- Icelandic
  (PDF/30.33 KB)
- Italian
  (PDF/29.01 KB)
- Latvian
  (PDF/65.13 KB)
- Lithuanian
  (PDF/65.13 KB)
- Maltese
  (PDF/67.26 KB)
- Norwegian
  (PDF/28.2 KB)
- Polish
  (PDF/49.5 KB)
- Portuguese
  (PDF/29.91 KB)
- Romanian
  (PDF/63.84 KB)
- Slovak
  (PDF/51.54 KB)
- Slovenian
  (PDF/60.9 KB)
- Spanish
  (PDF/29.91 KB)
- Swedish
  (PDF/29.93 KB)
List item

Competact-H-C-655-PSUV-43 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/102.06 KB)

Adopted

First published: 19/12/2013
Last updated: 19/12/2013
EMA/CHMP/566874/2013
List item

Competact-H-C-655-A20-30 : EPAR - Assessment Report - Article 20 (PDF/223.23 KB)

Adopted

First published: 07/05/2012
Last updated: 07/05/2012
EMA/CHMP/940059/2011

Competact

Table of contents

Overview

Competact : EPAR - Summary for the public (PDF/78.11 KB)

Competact : EPAR - Risk-management-plan summary (PDF/250.61 KB)

Authorisation details

Product information

Competact : EPAR - Product Information (PDF/373.22 KB)

Competact : EPAR - All Authorised presentations (PDF/91.12 KB)

Competact : EPAR - Conditions imposed on member states for safe and effective use (PDF/17.07 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Competact : EPAR - Procedural steps taken and scientific information after authorisation (PDF/248.32 KB)

Competact-H-C-PSUSA-00002417-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/69.46 KB)

Competact-H-A-31-1432-C-655-0060 : EPAR - Assessment Report - Article 31 (PDF/568.79 KB)

Competact : EPAR - Scientific Conclusion (PDF/32.54 KB)

Competact-H-C-655-PSUV-43 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/102.06 KB)

Competact-H-C-655-A20-30 : EPAR - Assessment Report - Article 20 (PDF/223.23 KB)

Initial marketing-authorisation documents

Competact : EPAR - Procedural steps taken before authorisation (PDF/24.81 KB)

Competact : EPAR - Scientific Discussion (PDF/342.72 KB)

News

Related content

How useful was this page?